| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | PF-4800567 hydrochloride | CTRPv2 | pan-cancer | AAC | 0.035 | 0.6 |
| mRNA | temsirolimus | CTRPv2 | pan-cancer | AAC | 0.03 | 0.6 |
| mRNA | fulvestrant | CTRPv2 | pan-cancer | AAC | 0.046 | 0.6 |
| mRNA | SNX-2112:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.021 | 0.6 |
| mRNA | BMS-270394 | CTRPv2 | pan-cancer | AAC | 0.023 | 0.6 |
| mRNA | BRD6340 | CTRPv2 | pan-cancer | AAC | 0.022 | 0.6 |
| mRNA | BRD-K35604418 | CTRPv2 | pan-cancer | AAC | 0.023 | 0.6 |
| mRNA | BRD-K42260513 | CTRPv2 | pan-cancer | AAC | -0.036 | 0.6 |
| mRNA | Docetaxel | CTRPv2 | pan-cancer | AAC | 0.03 | 0.6 |
| mRNA | masitinib | CTRPv2 | pan-cancer | AAC | 0.022 | 0.6 |